We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.77%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.73B
AUM Growth
+$1.49B
Cap. Flow
+$225M
Cap. Flow %
2.57%
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
80
Reduced
68
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$143M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$63.9M
3
MRSN
Mersana Therapeutics
MRSN
+$42.8M
4
DXCM icon
DexCom
DXCM
+$32.7M
5
ABBV icon
AbbVie
ABBV
+$32.5M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$154M
2
HALO icon
Halozyme
HALO
+$51.2M
3
CRL icon
Charles River Laboratories
CRL
+$49.6M
4
CDNA icon
CareDx
CDNA
+$44.7M
5
MDT icon
Medtronic
MDT
+$40.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
2 Technology 0.6%
3 Industrials 0.33%
4 Financials 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
51
Insmed
INSM
$23.2B
$53.8M 0.62%
1,617,000
+396,831
+33% +$14.5M
MRSN
52
DELISTED
Mersana Therapeutics
MRSN
$51.3M 0.59%
+77,040
New +$42.8M
EVH icon
53
Evolent Health
EVH
$667M
$50.5M 0.58%
3,149,111
-124,214
-4% -$1.64M
AMGN icon
54
Amgen
AMGN
$197B
$50.1M 0.57%
217,990
+38,377
+21% +$8.85M
TFX icon
55
Teleflex
TFX
$5.93B
$48.5M 0.56%
117,778
+39,134
+50% +$14.4M
BDTX icon
56
Black Diamond Therapeutics
BDTX
$104M
$45M 0.52%
1,403,000
– –
SWAV
57
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$44.1M 0.51%
425,335
-35,918
-8% -$3.11M
PACB icon
58
Pacific Biosciences
PACB
$422M
$44.1M 0.5%
1,698,179
-2,206,288
-57% -$37.5M
MOH icon
59
Molina Healthcare
MOH
$12B
$42.5M 0.49%
199,688
+35,116
+21% +$7.25M
TDOC icon
60
Teladoc Health
TDOC
$1.74B
$42.1M 0.48%
210,352
+88,998
+73% +$18.1M
DVA icon
61
DaVita
DVA
$15B
$41.5M 0.47%
353,200
+26,800
+8% +$2.73M
ABBV icon
62
AbbVie
ABBV
$448B
$40.2M 0.46%
375,500
+338,500
+915% +$32.5M
IDXX icon
63
Idexx Laboratories
IDXX
$44.5B
$39M 0.45%
78,085
-313
-0.4% -$140K
GMED icon
64
Globus Medical
GMED
$10.3B
$38.1M 0.44%
584,612
+174,877
+43% +$10.1M
BAX icon
65
Baxter International
BAX
$11.4B
$38.1M 0.44%
474,623
– –
GNMK
66
DELISTED
GenMark Diagnostics, Inc
GNMK
$38.1M 0.44%
2,606,636
+1,342,825
+106% +$17.8M
ZBH icon
67
Zimmer Biomet
ZBH
$17.4B
$37.7M 0.43%
252,104
+19,592
+8% +$2.77M
BIO icon
68
Bio-Rad Laboratories Class A
BIO
$8.08B
$37.5M 0.43%
64,405
-13,781
-18% -$7.85M
TNDM icon
69
Tandem Diabetes Care
TNDM
$1.24B
$36.9M 0.42%
385,184
+71,740
+23% +$7.39M
CRL icon
70
Charles River Laboratories
CRL
$10.6B
$35.7M 0.41%
143,018
-208,065
-59% -$49.6M
OMCL icon
71
Omnicell
OMCL
$2.06B
$35.6M 0.41%
296,303
+17,882
+6% +$1.75M
ABMD
72
DELISTED
Abiomed Inc
ABMD
$34.9M 0.4%
107,557
+6,159
+6% +$1.7M
GKOS icon
73
Glaukos
GKOS
$9.13B
$33.8M 0.39%
449,332
-66,422
-13% -$4.2M
CHNG
74
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$33.3M 0.38%
1,785,974
+88,035
+5% +$1.45M
QTRX icon
75
Quanterix
QTRX
$184M
$33.2M 0.38%
712,999
-10,675
-1% -$466K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2020 Portfolio in Review

As of Q4 2020, Bellevue Group held 234 positions worth $8.73B, up 21% from $7.24B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group's Q4 2020 filing shows 17 new, 80 increased, 68 reduced and 12 closed positions. Its largest new stake was Mersana Therapeutics: 77,040 shares worth $51.3M. The largest sale was MyoKardia, Inc. Common Stock, an estimated $154M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q4 2020 buy was Mersana Therapeutics: 77,040 shares worth $51.3M.
  • Bellevue Group added most to Biogen in Q4 2020, an estimated $143M increase.
  • Bellevue Group's biggest Q4 2020 reduction was Halozyme, cutting an estimated $51.2M.
  • Bellevue Group fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $154M.
  • Bellevue Group's ten largest holdings make up 32% of its $8.73B portfolio in Q4 2020.
  • Bellevue Group opened 17 new positions and closed 12 in Q4 2020.
  • Bellevue Group's portfolio value rose 21% quarter-over-quarter to $8.73B.

Based on Bellevue Group's 13F filing for Q4 2020, filed 16 Feb 2021.